The 60-second home check gaining weight in feline HCM care
Bottom line
A simple home check, counting a cat’s resting or sleeping breaths for 60 seconds, is getting renewed attention as feline hypertrophic cardiomyopathy care shifts from watchful waiting to more active long-term management. Veterinary Practice News highlighted the role of resting respiratory rate monitoring in cats with HCM, especially as new treatment options emerge and more cats may be followed earlier in the course of disease. That emphasis aligns with the ACVIM consensus statement, which recommends pet parents monitor resting or sleeping respiratory rate at home, particularly once left atrial enlargement raises concern for progression, and with recent technician-focused guidance that calls trend tracking a practical way to catch early decompensation. Normal resting values are typically under 30 breaths per minute, and gradual increases can be an early sign of congestive heart failure. (veterinarypracticenews.com)
Why it matters: For veterinary teams, the point isn’t just teaching pet parents how to count breaths, it’s building structured follow-up around that data. Feline HCM often stays clinically silent until congestive heart failure, arterial thromboembolism, or sudden death occurs, so a low-cost, repeatable home metric can help flag change earlier between rechecks. That becomes more relevant as the therapeutic landscape evolves: in March 2025, the FDA conditionally approved Felycin-CA1 (sirolimus delayed-release tablets) for management of ventricular hypertrophy in cats with subclinical HCM, and the ongoing HALT HCM study is evaluating longer-term use of once-weekly delayed-release rapamycin in early-stage disease. In other words, earlier detection and more disciplined monitoring may matter more now than when there were few intervention options beyond supportive care. (veterinarypracticenews.com)
What to watch: Expect more emphasis on standardized client education, trend-based home monitoring, and real-world use of newer HCM therapies as longer-term trial data mature. (vetmed.iastate.edu)
Key facts
- Condition
- Feline hypertrophic cardiomyopathy (HCM)
- Home monitoring
- Count resting or sleeping breaths for 60 seconds
- Normal resting respiratory rate
- Typically under 30 breaths per minute
- Early warning sign
- Gradual increases in resting respiratory rate can signal congestive heart failure
- FDA action
- Conditionally approved Felycin-CA1 in March 2025
- Drug
- Felycin-CA1 (sirolimus delayed-release tablets)
- Indication
- Management of ventricular hypertrophy in cats with subclinical HCM
- Study
- HALT HCM is evaluating once-weekly delayed-release rapamycin in early-stage disease
- Trial finding
- RAPACAT data showed halted progression of left ventricular hypertrophy over six months in enrolled cats with subclinical, nonobstructive HCM
A 60-second home breathing check is becoming a more important part of feline hypertrophic cardiomyopathy management, not because it’s new, but because the stakes around early change detection are rising. Veterinary Practice News framed resting respiratory rate monitoring as one of the most effective tools for following feline cardiac patients at home, with veterinary technicians often leading the education that turns a simple count into actionable surveillance. (veterinarypracticenews.com)
That message lands in a different clinical environment than it did a few years ago. Feline HCM remains the most commonly diagnosed cardiac disease in cats, and it can progress quietly until a cat presents in respiratory distress, develops arterial thromboembolism, or dies suddenly. The ACVIM consensus statement has long supported home monitoring of resting or sleeping respiratory rate, and more recent clinical education materials from the Cardiac Education Group continue to strongly recommend it for cats with more advanced subclinical disease. (veterinarypracticenews.com)
The practical advice is straightforward: count breaths while the cat is asleep or fully resting, and track trends over time rather than relying on a single number. Veterinary Practice News reported that normal values are typically under 30 breaths per minute, echoing guidance from academic and clinical sources. North Carolina State’s cardiology guidance similarly tells pet parents that monitoring sleeping breathing rate can help detect early signs of congestive heart failure, and published data on sleeping and resting respiratory rates provide the reference framework clinicians use when deciding whether a rate is elevated. (veterinarypracticenews.com)
What’s changed is the treatment backdrop. In March 2025, the FDA conditionally approved Felycin-CA1, a delayed-release sirolimus product from TriviumVet, for management of ventricular hypertrophy in cats with subclinical HCM. The approval followed RAPACAT trial data showing that once-weekly delayed-release rapamycin over six months was associated with halted progression of left ventricular hypertrophy in enrolled cats with subclinical, nonobstructive HCM. Veterinary Practice News’ earlier symposium coverage described the approval as a meaningful shift for a disease area that historically had few treatment options, while also noting important safety considerations, including a diabetes-related death in one pre-diabetic study cat. (fda.gov)
Industry and expert commentary reflects that sense of cautious change. In symposium remarks reported by Veterinary Practice News, Joshua Stern, DVM, PhD, said the data supporting rapamycin had been building for years, and Brian Peters, DVM, described the arrival of a therapy that may reduce catastrophic complications of HCM as a major step for practitioners and pet parents. At the same time, the Feline Veterinary Medical Association’s 2026 client handout stresses that newer medication may help slow or possibly reverse early HCM only in certain cats, is still being studied, and is not appropriate for cats with diabetes or liver disease. (veterinarypracticenews.com)
Why it matters: For veterinary professionals, structured home monitoring is becoming less of a nice-to-have and more of a care pathway issue. If more cats with subclinical HCM are identified earlier, whether through screening, biomarkers, referral echocardiography, or access to newer therapies, practices will need reliable systems for coaching pet parents, documenting baseline resting respiratory rate, defining escalation thresholds, and integrating technician follow-up. A 60-second check is only useful if the clinic has a plan for what happens when the number drifts upward, or when breathing effort changes even before the rate crosses an arbitrary cutoff. That’s especially important in a disease known for silent progression and uneven access to cardiology referral. (veterinarypracticenews.com)
There’s also an operational point here. Home respiratory monitoring is inexpensive, scalable, and easy to reinforce during discharge, recheck scheduling, medication counseling, and tele-triage. In a field where specialist access remains limited and treatment decisions are increasingly individualized, it gives general practice teams and technicians a concrete way to extend surveillance beyond the exam room. That may improve the odds of catching congestive heart failure earlier, when intervention can be more controlled and less crisis-driven. This is an inference based on consensus guidance and client-education materials that position increased resting respiratory rate as an early sign of heart failure. (pmc.ncbi.nlm.nih.gov)
What to watch: The next signal will be whether structured home monitoring becomes more formalized alongside broader uptake of Felycin-CA1 and enrollment in longer-term studies such as HALT HCM, which is still evaluating once-weekly therapy in cats with early-stage disease. (vetmed.iastate.edu)